Osteoclast-derived complement component 3a stimulates osteoblast differentiation

Journal of Bone and Mineral Research

Volumn 29, Issue 7, 2014, Pages 1522-1530

  Matsuoka, Kazuhiko ^a   Park, Kyoung Ae ^a   Ito, Masako ^b   Ikeda, Kyoji ^a   Takeshita, Sunao ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

MOLECULAR PATHWAYS REMODELING < BONE MODELING AND REMODELING; OSTEOBLASTS < CELLS OF BONE; OSTEOCLASTS < CELLS OF BONE

Indexed keywords

ALKALINE PHOSPHATASE; COMPLEMENT COMPONENT C3A; OSTEOCLAST DIFFERENTIATION FACTOR; CULTURE MEDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; GENE EXPRESSION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; PROTEIN PURIFICATION; ANIMAL; BONE DEVELOPMENT; C57BL MOUSE; CELL DIFFERENTIATION; CHROMATOGRAPHY; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; PHARMACOLOGY;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CHROMATOGRAPHY; COMPLEMENT C3A; CULTURE MEDIA, CONDITIONED; FEMALE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OVARIECTOMY;

EID: 84903280959     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2187     Document Type: Article

References (39)

1. Zaidi M., Skeletal remodeling in health and disease. Nat Med. 2007; 13 (7): 791-801.
2. Hattner R, Epker BN, Frost HM., Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965; 206 (983): 489-90.
3. Martin TJ, Sims NA., Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005; 11 (2): 76-81.
4. Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15 (7): 757-65.
5. Xian L, Wu X, Pang L, et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med. 2012; 18 (7): 1095-101.
6. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006; 4 (2): 111-21.
7. Takeshita S, Fumoto T, Matsuoka K, et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. J Clin Invest. 2013; 123 (9): 3914-24.
8. Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH., Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. Embo J. 2006; 25 (24): 5840-51.
9. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ., Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA. 2008; 105 (52): 20764-9.
10. Walker EC, McGregor NE, Poulton IJ, et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res. 2008; 23 (12): 2025-32.
11. Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013; 123 (2): 666-81.
12. Takeshita S, Namba N, Zhao JJ, et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med. 2002; 8 (9): 943-9.
13. Takeshita S, Kaji K, Kudo A., Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res. 2000; 15 (8): 1477-88.
14. Takahashi N, Akatsu T, Udagawa N, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology. 1988; 123 (5): 2600-2.
15. Katagiri T, Yamaguchi A, Komaki M, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol. 1994; 127 (6 Pt 1): 1755-66.
16. Indo Y, Takeshita S, Ishii KA, et al. Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res. 2013; 28 (11): 2392-9.
17. Ito M, Ikeda K, Nishiguchi M, et al. Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk. J Bone Miner Res. 2005; 20 (10): 1828-36.
18. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25 (7): 1468-86.
19. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28 (1): 2-17.
20. Walport MJ., Complement. Second of two parts. N Engl J Med. 2001; 344 (15): 1140-4.
21. Walport MJ., Complement. First of two parts. N Engl J Med. 2001; 344 (14): 1058-66.
22. Ames RS, Lee D, Foley JJ, et al. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol. 2001; 166 (10): 6341-8.
23. Hutamekalin P, Takeda K, Tani M, et al. Effect of the C3a-receptor antagonist SB 290157 on anti-OVA polyclonal antibody-induced arthritis. J Pharmacol Sci. 2010; 112 (1): 56-63.
24. Asgari E, Le Friec G, Yamamoto H, et al. C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. 2013; 122 (20): 3473-81.
25. Tomimori Y, Mori K, Koide M, et al. Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J Bone Miner Res. 2009; 24 (7): 1194-205.
26. Sato T, Abe E, Jin CH, et al. The biological roles of the third component of complement in osteoclast formation. Endocrinology. 1993; 133 (1): 397-404.
27. Tu Z, Bu H, Dennis JE, Lin F., Efficient osteoclast differentiation requires local complement activation. Blood. 2010; 116 (22): 4456-63.
28. Mamane Y, Chung Chan C, Lavallee G, et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes. 2009; 58 (9): 2006-17.
29. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000; 100 (2): 197-207.
30. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002; 111 (3): 305-17.
31. Henriksen K, Bollerslev J, Everts V, Karsdal MA., Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev. 2011; 32 (1): 31-63.
32. Dunkelberger JR, Song WC., Complement and its role in innate and adaptive immune responses. Cell Res. 2010; 20 (1): 34-50.
33. Kang YS, Do Y, Lee HK, et al. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell. 2006; 125 (1): 47-58.
34. Sato T, Hong MH, Jin CH, et al. The specific production of the third component of complement by osteoblastic cells treated with 1 alpha,25-dihydroxyvitamin D3. FEBS Lett. 1991; 285 (1): 21-4.
35. Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. 2008; 28 (3): 425-35.
36. Strey CW, Markiewski M, Mastellos D, et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med. 2003; 198 (6): 913-23.
37. Taub R., Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol. 2004; 5 (10): 836-47.
38. He S, Atkinson C, Qiao F, Cianflone K, Chen X, Tomlinson S., A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest. 2009; 119 (8): 2304-16.
39. Schraufstatter IU, Discipio RG, Zhao M, Khaldoyanidi SK., C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol. 2009; 182 (6): 3827-36.